Business
Scilex Holding Company Generates Record Monthly Revenue In October 2023 And Provides Certain Preliminary Unaudited Financial Results For Gross And Net Sales For The One Month Ended October 2023, And Year-To-Date Through October 31, 2023, Based On Curr...
Scilex Holding Company Generates Record Monthly Revenue In October 2023 And Provides Certain Preliminary Unaudited Financial Results For Gross And Net Sales
About this update from Scilex Holding Company
[{"type":"text","content":"Scilex Holding Company Generates Record Monthly Revenue In October 2023 And Provides Certain Preliminary Unaudited Financial Results For Gross And Net Sales For The One Month Ended October 2023, And Year-To-Date Through October 31, 2023, Based On Currently Available Information \n PALO ALTO, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, announced record monthly revenue in October 2023 for ZTlido and provided certain preliminary unaudited financial results for gross and net sales for the one month ended October 2023 and year-to-date through October 31, 2023. The Company estimates that: Record ZTlido gross sales for October 2023 were in the range of $14.5 million to $15.5 million with record year-to-date gross sales through October 2023 in the range of $110.0 million to $120.0 million, compared to $74.8 million for year-to-date through October 2022, representing growth in the range of 47% to 60%. Full year gross sales for ZTlido in 2022 were $96.0 million.ZTlido net sales for October 2023 were in the range of $4.0 million to $5.0 million with year-to-date net sales through October 2023 in the range of $35.0 million to $40.0 million, compared to $30.4 million for year-to-date through October 2022, representing growth in the range of 15% to 32%. Full year net sales for ZTlido in 2022 were $38.0 million.Total product gross sales for October 2023 were in the range of $15.5 million to $16.5 million with year-to-date total product gross sales through October 2023 in the range of $115.0 million to $125.0 million, compared to $74.8 million for year-to-date through October 2022, representing growth in the range of 54% to 67%.Total product net sales for October 2023 were in the range of $4.0 million to $5.0 million with year-to-date total product net sales through October 2023 in the range of $35.0 million to $40.0 million, compared to $30.4 million for year-to-date October 2022, representing growth in the range of 15% to 32%. About Scilex Holding Company Scilex Holding Company is an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for...